Overview

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tablet
Phase:
Phase 3
Details
Lead Sponsor:
Warner Chilcott
Treatments:
Mesalamine